Literature DB >> 10424677

Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters.

S Luo1, J Luo, A H Cincotta.   

Abstract

A critical role for temporal organization of dopaminergic and serotonergic activities within the suprachiasmatic nuclei (SCN) in the regulation of peripheral glucose metabolism has been postulated. This study employed in vivo microdialysis to investigate the temporal extracellular profiles of dopamine and serotonin metabolites in the SCN of freely behaving naturally glucose tolerant and intolerant Syrian hamsters. Microdialysis samples from the right SCN of awake, glucose tolerant or intolerant hamsters held on 14 h daily photoperiods were collected every 2 h over a 24 h period and assayed via HPLC for the metabolites of dopamine: homovanillic acid (HVA) and serotonin (5-hydroxyindolacetic acid, 5-HIAA). Among glucose tolerant hamsters, daily rhythms of SCN HVA and 5-HIAA were observed with coincident plateaus throughout the nocturnal phase of the day (both p<0.01). Relative to glucose tolerant hamsters, glucose intolerant animals exhibited a loss in the daily rhythm of SCN HVA (p<0.0001) and 5-HIAA (p<0.02) due to marked reductions (70%) throughout the 24 h period in HVA levels and comparative decreases (35%) in nocturnal peak levels of 5-HIAA. These findings demonstrate that daily profiles of extracellular dopamine and serotonin activities in the SCN, known to influence glucose metabolism, differ between glucose tolerant and intolerant hamsters.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424677     DOI: 10.1097/00001756-199907130-00015

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  13 in total

Review 1.  Mechanisms of current therapies for diabetes mellitus type 2.

Authors:  Peter M Thulé
Journal:  Adv Physiol Educ       Date:  2012-12       Impact factor: 2.288

2.  Bromocriptine mesylate improves glucose tolerance and disposal in a high-fat-fed canine model.

Authors:  Mary Courtney Moore; Marta S Smith; Larry L Swift; Anthony H Cincotta; Michael Ezrokhi; Nicholas Cominos; Yahong Zhang; Ben Farmer; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-05-27       Impact factor: 4.310

Review 3.  Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.

Authors:  Ralph A Defronzo
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

4.  Bromocriptine in type 2 diabetes mellitus.

Authors:  C Shivaprasad; Sanjay Kalra
Journal:  Indian J Endocrinol Metab       Date:  2011-07

5.  Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats.

Authors:  Michael Ezrokhi; Shuqin Luo; Yelena Trubitsyna; Anthony H Cincotta
Journal:  Diabetol Metab Syndr       Date:  2014-09-25       Impact factor: 3.320

6.  Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.

Authors:  Bindu Chamarthi; J Michael Gaziano; Lawrence Blonde; Aaron Vinik; Richard E Scranton; Michael Ezrokhi; Dean Rutty; Anthony H Cincotta
Journal:  J Diabetes Res       Date:  2015-04-28       Impact factor: 4.011

7.  Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.

Authors:  Erin D Roe; Bindu Chamarthi; Philip Raskin
Journal:  J Diabetes Res       Date:  2015-04-28       Impact factor: 4.011

8.  Sleep restriction acutely impairs glucose tolerance in rats.

Authors:  Pawan K Jha; Ewout Foppen; Andries Kalsbeek; Etienne Challet
Journal:  Physiol Rep       Date:  2016-06

9.  Circadian peak dopaminergic activity response at the biological clock pacemaker (suprachiasmatic nucleus) area mediates the metabolic responsiveness to a high-fat diet.

Authors:  S Luo; Y Zhang; M Ezrokhi; Y Li; T-H Tsai; A H Cincotta
Journal:  J Neuroendocrinol       Date:  2018-01       Impact factor: 3.627

10.  Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.

Authors:  Michael Ezrokhi; Yahong Zhang; Shuqin Luo; Anthony H Cincotta
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.